Lenvima

Description

Lenvima
Differentiated thyroid cancer. The drug is indicated for use as monotherapy in adult patients with progressive locally advanced or metastatic differentiated thyroid cancer refractory to radioactive iodine therapy;
Hepatocellular carcinoma (HCC). The drug is indicated for use as monotherapy in adult patients with advanced or inoperable hepatocellular cancer who have not previously received systemic therapy;
Renal cell carcinoma (RCC). Lenvima is indicated for use in combination with pembrolizumab as first-line therapy in adult patients with advanced renal cell carcinoma. Lenvima is indicated for use in combination with everolimus in adult patients with advanced renal cell carcinoma, after one previous course of targeted therapy with vascular endothelial growth factor receptor inhibitors;
Active ingredient: lenvatinib

Prescription drug.